Shots:
- Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics, expanding Lilly’s genetic medicine capabilities
- As per the deal, Lilly will acquire Kelonia for ~$7B in cash, incl. $3.25B upfront, & additional clinical, regulatory & commercial milestone payments; closing expected in H2’26
- Acquisition will add Kelonia’s in vivo gene placement system (iGPS0) & its lead asset, KLN-1010, a one-time IV gene therapy that generates anti-B-cell maturation antigen CAR-T cells, for the treatment of multiple myeloma
Ref: Kelonia Therapeutics | Image: Kelonia Therapeutics |Press Release
Related News: Eli Lilly to Acquire CrossBridge Bio for ~$300M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
